David B. Solit

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer

  Clinical Cancer Research · 2026-06-26

• Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers

  medRxiv · 2026-06-22

• Supplementary Sequencing Data1 from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer

  2026-06-17

• Supplementary tables/figures1 from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer

  2026-06-17

• Data from Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non–Muscle-Invasive Bladder Cancer

  2026-06-17

• Genomic determinants of cisplatin resistance in germ cell tumors.

  Journal of Clinical Oncology · 2026-05-27

• IP36-04 INTEGRATIVE CLINICAL AND MOLECULAR CHARACTERIZATION OF METASTASIS AND RESISTANCE TO ANTIBODY-DRUG CONJUGATES IN SARCOMATOID VARIANT BLADDER CANCER

  The Journal of Urology · 2026-04-27

• IP44-13 DISEASE PRESENTATION AND ONCOLOGIC OUTCOMES OF EARLY-ONSET PROSTATE CANCER IN A CONTEMPORARY COHORT

  The Journal of Urology · 2026-04-27

• Cancer type-specific variation in patterns of driver alterations across 50,000 tumors

  Cancer Cell · 2026-04-18

• Abstract 6059: Vertical MAPK pathway targeting is required for tumor regression in novel human and mouse models of NF1-inactivated melanoma

  Cancer Research · 2026-04-03

• Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma

  JCO Precision Oncology · 2026-04-01

• Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer

  Nature Communications · 2025-12-20 · 5 citations

• Data from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Table 5 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Materials and Methods from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Table 1, Supplemental Table 2, Supplemental Table 3, Supplemental Table 6, Supplemental Table 7, Supplemental Figure 1, and Supplemental Figure 2 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplemental Table 4 from Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations

  2025-12-17

• Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10

• Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer

  2025-12-10